Login
Super Investors SILVERARC CAPITAL MANAGEMENT, LLC
SC

SILVERARC CAPITAL MANAGEMENT, LLC

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$854M
Positions
70
Quarter ended
September 30, 2026
Filed
November 12, 2026

Reported portfolio value by quarter (24 quarters reported)

$980M $172M
Q4 20 Q1 22 Q2 23 Q3 24 Q4 25 Q3 26

$172M in Q4 2020 → $854M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Kodiak Sciences Inc 8.3% Added 37% 750,170 $71.1M
Celcuity Inc 7.5% Added 60% 803,193 $63.9M
Cogent Biosciences Inc 5.9% Added 23% 1,574,698 $50.4M
Urogen Pharma Ltd 5.5% Trimmed 12% 1,148,689 $46.7M
Immunome Inc 5.3% Added 3.8% 2,092,715 $45M
Monte Rosa Therapeutics Inc 4.3% Added 181% 3,112,773 $37.1M
Sagimet Biosciences Inc 4.3% Added 28% 3,745,990 $37M
Ascendis Pharma A/s 4.1% Trimmed 26% 152,175 $34.7M
Rhythm Pharmaceuticals Inc 3.9% Added 12% 348,317 $33.2M
Biogen Inc 3.0% Added 134% 112,790 $25.5M
Immunovant Inc 2.5% Added 0.8% 624,055 $21.1M
Dianthus Therapeutics Inc 2.4% Trimmed 39% 236,582 $20.8M
Oruka Therapeutics Inc 2.4% Trimmed 30% 247,918 $20.6M
Erasca Inc 2.3% Added 5.3% 1,330,455 $19.5M
AS Abivax Sa 2.0% Added 3.6% 175,699 $17.4M
CT Celldex Therapeutics Inc New 1.8% New 487,589 $15.8M
Ovid Therapeutics Inc 1.7% Added 92% 5,950,000 $14.8M
Spyre Therapeutics Inc 1.6% Added 152% 151,151 $13.5M
Definium Therapeutics Inc 1.5% Trimmed 14% 345,946 $13.2M
Helix Acquisition Corp Iii 1.5% Added 2.6% 1,208,030 $12.8M
Alkermes PLC 1.4% Added 165% 300,427 $12.2M
CT Celldex Therapeutics Inc New Call 1.4% New 370,700 $12M
C4 Therapeutics Inc 1.3% Added 14% 3,454,647 $11.5M
AP Avalyn Pharmaceuticals Inc 1.3% Added 14% 378,352 $10.8M
Oric Pharmaceuticals Inc Call 1.1% Added 2.9% 702,400 $9.46M
Cerus Corp 1.1% Added 14% 3,950,595 $9.4M
AO Alx Oncology Hldgs Inc 1.1% Added 14% 6,565,960 $9.13M
Zenas Biopharma Inc 1.1% Trimmed 34% 334,057 $9.01M
Compass Pathways PLC 1.0% Added 43% 717,356 $8.92M
RA Rainier Acquisition Corp 1.0% New 853,875 $8.71M
Compugen Ltd 1.0% Added 13% 3,586,785 $8.54M
Savara Inc 0.9% Added 12% 1,518,833 $7.84M
Vaxcyte Inc 0.8% Trimmed 14% 125,080 $7.12M
Yarrow Bioscience Inc 0.8% New 301,919 $6.8M
Ibio Inc 0.7% Added 52% 5,357,088 $6.32M
AT Arcturus Therapeutics Hldgs 0.7% New 459,899 $6.3M
Monte Rosa Therapeutics Inc Call 0.7% Added 75% 525,000 $6.26M
PP Praxis Precision Medicines I 0.7% Trimmed 70% 19,753 $5.75M
KP Kiniksa Pharmaceuticals Intl 0.7% New 75,697 $5.65M
Enliven Therapeutics Inc 0.7% Trimmed 75% 121,452 $5.57M
Solid Biosciences Inc 0.6% Added 14% 760,337 $5.5M
Evommune Inc 0.6% New 594,027 $4.91M
Syndax Pharmaceuticals Inc 0.5% Trimmed 80% 247,418 $4.65M
Benitec Biopharma Inc 0.5% Trimmed 35% 443,109 $4.43M
Research Alliance Corp Iii 0.5% Added 12% 404,728 $4.38M
BT Blossomhill Therapeutics Inc 0.4% New 202,104 $3.77M
Faeth Therapeutics Inc 0.4% New 124,098 $3.69M
Abeona Therapeutics Inc 0.4% Added 14% 693,441 $3.64M
RA Research Alliance Corp Iv 0.4% New 301,962 $3.5M
Adlai Nortye Group Ltd 0.4% New 216,617 $3.47M
Palisade Bio Inc 0.4% New 2,335,602 $3.15M
Disc Medicine Inc 0.4% Trimmed 43% 47,312 $3.1M
Absci Corporation Put 0.3% Added 62% 254,700 $2.74M
Tela Bio Inc 0.3% Unchanged 2,137,201 $2.46M
Zevra Therapeutics Inc 0.3% New 200,260 $2.2M
Oric Pharmaceuticals Inc 0.3% Trimmed 78% 160,552 $2.16M
Contineum Therapeutics Inc 0.2% Trimmed 46% 158,964 $2.13M
Moderna Inc 0.2% New 10,000 $1.93M
Elutia Inc 0.2% Unchanged 2,192,980 $1.73M
Fulcrum Therapeutics Inc Call 0.2% Unchanged 391,900 $1.45M

Showing top 60 of 70 positions.

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 12, 2026

Company Action Shares changed Value of change % of portfolio
Celcuity Inc Added +302,197 +$24M 7.5%
Monte Rosa Therapeutics Inc Added +2,004,478 +$23.9M 4.3%
AE Ark ETF Tr Exited −500,000 −$21M —
Kodiak Sciences Inc Added +203,914 +$19.3M 8.3%
Veracyte Inc Exited −318,001 −$18.7M —
Syndax Pharmaceuticals Inc Trimmed −966,972 −$18.2M 0.5%
Enliven Therapeutics Inc Trimmed −367,930 −$16.9M 0.7%
CT Celldex Therapeutics Inc New New +487,589 +$15.8M 1.8%
Syndax Pharmaceuticals Inc Exited −693,600 −$15.2M —
Guardant Health Inc Exited −99,826 −$15M —

Showing the 10 largest of 88 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 13, 2026

Company Action Shares changed Value of change % of portfolio
SS SPDR Series Trust Exited −825,000 −$105M —
Kalvista Pharmaceuticals Inc Exited −2,876,407 −$57.9M —
Ascendis Pharma A/s New +206,234 +$55M 5.7%
Nuvalent Inc Exited −354,914 −$36.4M —
Ascendis Pharma A/s Exited −124,658 −$28.5M —
Dianthus Therapeutics Inc Trimmed −264,746 −$25.8M 4.0%
Enliven Therapeutics Inc New +489,382 +$24.8M 2.6%
Sagimet Biosciences Inc New +2,927,698 +$22.6M 2.4%
Monte Rosa Therapeutics Inc Trimmed −893,745 −$21.6M 2.8%
AE Ark ETF Tr New +500,000 +$21M 2.2%

Showing the 10 largest of 96 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 14, 2026

Company Action Shares changed Value of change % of portfolio
SS SPDR Series Trust New +825,000 +$105M 10.8%
Zenas Biopharma Inc New +1,135,935 +$22.2M 2.3%
Ascendis Pharma A/s Added +75,430 +$17.3M 2.9%
SR Scholar Rock Hldg Corp New +339,613 +$16.7M 1.7%
Alkermes PLC New +460,314 +$16.3M 1.7%
Monte Rosa Therapeutics Inc Added +972,974 +$16M 3.4%
Immunome Inc Added +724,068 +$15.8M 4.1%
Rhythm Pharmaceuticals Inc Added +170,050 +$14.8M 2.7%
AS Abivax Sa Trimmed −119,663 −$13.3M 3.4%
Cg Oncology Inc Trimmed −194,809 −$13.2M 1.1%

Showing the 10 largest of 89 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 12, 2026

Company Action Shares changed Value of change % of portfolio
Avidity Biosciences Inc Exited −844,633 −$36.8M —
Akero Therapeutics Inc Exited −643,636 −$30.6M —
Celcuity Inc Added +286,446 +$28.6M 5.2%
UT United Therapeutics Corp Del Exited −59,900 −$25.1M —
Rhythm Pharmaceuticals Inc Trimmed −234,046 −$25.1M 2.0%
Immunome Inc New +1,126,210 +$24.2M 3.4%
Insmed Inc Trimmed −135,392 −$23.6M 1.7%
Cidara Therapeutics Inc Exited −220,902 −$21.2M —
Olema Pharmaceuticals Inc Trimmed −727,261 −$18.2M 0.7%
UN Uniqure Nv New +720,800 +$17.2M 2.4%

Showing the 10 largest of 101 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 12, 2025

Company Action Shares changed Value of change % of portfolio
AS Abivax Sa New +539,704 +$45.8M 6.2%
Merus N V Exited −741,972 −$39M —
Verona Pharma PLC Exited −358,297 −$33.9M —
UT United Therapeutics Corp Del New +59,900 +$25.1M 3.4%
Dianthus Therapeutics Inc Added +579,160 +$22.8M 3.6%
Neurocrine Biosciences Inc Exited −162,969 −$20.5M —
Merus N V Exited −382,500 −$20.1M —
89bio Inc Exited −2,037,087 −$20M —
Avidity Biosciences Inc Added +434,633 +$18.9M 5.0%
Soleno Therapeutics Inc Exited −204,591 −$17.1M —

Showing the 10 largest of 98 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Merus N V New +382,500 +$20.1M 3.7%
Verona Pharma PLC Trimmed −187,575 −$17.7M 6.2%
SS SPDR Series Trust New +200,000 +$16.6M 3.1%
Nuvalent Inc Trimmed −203,435 −$15.5M 3.3%
Cg Oncology Inc New +541,034 +$14.1M 2.6%
SR Scholar Rock Hldg Corp New +341,010 +$12.1M 2.2%
Disc Medicine Inc Exited −236,471 −$11.7M —
Neurocrine Biosciences Inc Added +90,386 +$11.4M 3.8%
Vaxcyte Inc New +287,796 +$9.36M 1.7%
Urogen Pharma Ltd Added +641,324 +$8.79M 5.1%

Showing the 10 largest of 85 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 14, 2025

Company Action Shares changed Value of change % of portfolio
Pliant Therapeutics Inc Exited −1,315,601 −$17.3M —
IT Intra-cellular Therapies Inc Exited −179,085 −$15M —
Kalvista Pharmaceuticals Inc Added +1,086,811 +$12.5M 4.0%
Soleno Therapeutics Inc New +166,417 +$11.9M 2.4%
89bio Inc Added +1,413,987 +$10.3M 2.2%
Poseida Therapeutics Inc Exited −1,012,307 −$9.72M —
Neurocrine Biosciences Inc New +72,583 +$8.03M 1.6%
SR Scholar Rock Hldg Corp Exited −183,243 −$7.92M —
Cogent Biosciences Inc Exited −921,137 −$7.18M —
Disc Medicine Inc Added +126,090 +$6.26M 2.4%

Showing the 10 largest of 83 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
Poseida Therapeutics Inc Trimmed −2,675,241 −$25.7M 2.1%
Pliant Therapeutics Inc New +1,315,601 +$17.3M 3.8%
Syndax Pharmaceuticals Inc Added +851,654 +$11.3M 3.6%
Alnylam Pharmaceuticals Inc Exited −35,774 −$9.84M —
SR Scholar Rock Hldg Corp New +183,243 +$7.92M 1.7%
Verona Pharma PLC Added +167,148 +$7.76M 5.2%
Protagonist Therapeutics Inc Exited −146,657 −$6.6M —
Ascendis Pharma A/s Added +46,491 +$6.4M 1.6%
Sarepta Therapeutics Inc Exited −51,245 −$6.4M —
Akero Therapeutics Inc New +220,000 +$6.12M 1.3%

Showing the 10 largest of 83 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support